Meeting
2023 ASCO Annual Meeting
Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies.
Authors
Andreas Rimner
Memorial Sloan Kettering Cancer Center, New York, NY
Andreas Rimner , James Huang , Andrew Pagano , Michelle S. Ginsberg , Jason C. Chang , Gregory J. Riely , Charles B. Simone II, Daniel Richard Gomez , Annemarie Shepherd
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Thymic Malignancies
Clinical Trial Registration Number
NCT05354570
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8616)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8616
Abstract #
TPS8616
Poster Bd #
234b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma.
First Author: Kelsey Klute
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz
Poster
2022 ASCO Annual Meeting
GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer.
First Author: Sarah E. Hoffe
Poster
2018 ASCO Annual Meeting
Phase II trial of pembrolizumab (MK-3475) in metastatic cutaneous squamous cell carcinoma (cSCC).
First Author: Ragini Reiney Kudchadkar